Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
OwnerVirginia L. Smith-Swintoskyinventor
Life of this patent
Estimating the term…
Abstract
The present invention is a methods for neuroprotection, for treating an acute neurodegenerative disorder, for treating a chronic neurodegenerative disorder and/or for preventing neuron death or damage following brain, head and/or spinal cord trauma or injury comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined.
Claims40
A method for neuroprotection comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, trifluoromethyl, nitro and cyano;
- X—Y is selected from the group consisting of —S—CH—, —S—C(CH3)—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;
- A is selected from the group consisting of —CH2— and —CH(CH3)—;
- R2 is selected from the group consisting of hydrogen and methyl;
- R3 and R4 are each independently selected from the group consisting of hydrogen and C1-4alkyl;
- alternatively, R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;
- or a pharmaceutically acceptable salt thereof.
A method for neuroprotection comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide and pharmaceutically acceptable salts thereof.
A method of treating an acute neurodegenerative disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, trifluoromethyl, nitro and cyano;
- X—Y is selected from the group consisting of —S—CH—, —S—C(CH3)—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;
- A is selected from the group consisting of —CH2— and —CH(CH3)—;
- R2 is selected from the group consisting of hydrogen and methyl;
- R3 and R4 are each independently selected from the group consisting of hydrogen and C1-4alkyl;
- alternatively, R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;
- or a pharmaceutically acceptable salt thereof.
A method of treating an acute neurodegenerative disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide and pharmaceutically acceptable salts thereof.
A method of treating a chronic neurodegenerative disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, trifluoromethyl, nitro and cyano;
- X—Y is selected from the group consisting of —S—CH—, —S—C(CH3)—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;
- A is selected from the group consisting of —CH2— and —CH(CH3)—;
- R2 is selected from the group consisting of hydrogen and methyl;
- R3 and R4 are each independently selected from the group consisting of hydrogen and C1-4alkyl;
- alternatively, R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;
- or a pharmaceutically acceptable salt thereof.
A method of treating a chronic neurodegenerative disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide and pharmaceutically acceptable salts thereof.
A method for preventing neuron death or damage following brain, head or spinal cord trauma or injury comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, trifluoromethyl, nitro and cyano;
- X—Y is selected from the group consisting of —S—CH—, —S—C(CH3)—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;
- A is selected from the group consisting of —CH2— and —CH(CH3)—;
- R2 is selected from the group consisting of hydrogen and methyl;
- R3 and R4 are each independently selected from the group consisting of hydrogen and C1-4alkyl;
- alternatively, R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;
- or a pharmaceutically acceptable salt thereof.
A method for preventing neuron death or damage following brain, head or spinal cord trauma or injury comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.